USPTO serial 79028077
PAIONEERING
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOWRY, LEIGH A
- Law office
- TTAB
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PAIONEERING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gary D. Krugman
Gary D. Krugman Sughrue Mion, PLLC2100 Pennsylvania Ave., NWWashington, DC 20037-3213UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Research reagents; biochemical preparations for scientific purposes | ABANDONED | — |
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutraceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use; pharmaceutical preparations, namely, thrombolytic, fibrinolytic anti-coagulative, antithrombotical and neuroprotective substances for the treatment of blood clotting, cell protection and cell regeneration; products from biotechnological methods, namely, proteins for therapeutic and diagnostic use in the treatment and diagnosis of blood clotting disorders | ABANDONED | — |
| 010 | Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting blood specimen analysis of the human blood clotting system and for conducting medical diagnostic tests in the nature of medical apparatus for diagnosing suspected heart attacks, strokes, thrombosis, circulations and vascular disorders, embolisms, kidney failures, liver damages, infections, viral infections, sepsis, inflammatory and neuronal disorders | ABANDONED | — |
| 041 | Educational services, namely, providing seminars, educational exhibitions, correspondence courses, colloquiums, conferences, congresses, and workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics | ABANDONED | — |
| 042 | Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, performing pre-clinical studies, quality control; preparation of technical expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations; and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the areas the treatment and diagnosis of stroke, neuron damage, thrombotic diseases, heart diseases including heart failure, circulation disorders, gene expression analysis, namely, protogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins, diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technical research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment, scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others in the fields of prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Paion Deutschland GmbH
- Other trademarks owned by Paion Deutschland GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named PAIONEERING
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 9, 2016 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Dec 8, 2016 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Dec 13, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 2, 2010 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 12, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 12, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 1, 2009 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Dec 1, 2009 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Aug 12, 2009 | MAB4 | ABANDONMENT NOTICE MAILED - INTER PARTES DECISION | — |
| Aug 12, 2009 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Aug 12, 2009 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Aug 12, 2009 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Jul 18, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 18, 2009 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 23, 2009 | IRRF | IRREGULARITY ON REFUSAL FROM IB | — |
| May 6, 2009 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| May 5, 2009 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| May 5, 2009 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Jan 15, 2009 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Nov 24, 2008 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Nov 4, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 1, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 19, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2008 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2008 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 19, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Sep 19, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 11, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 7, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 4, 2008 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 4, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 4, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 28, 2008 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 13, 2008 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 13, 2008 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 6, 2008 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 5, 2008 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 16, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| May 16, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 16, 2007 | ALIE | ASSIGNED TO LIE | — |
| Apr 23, 2007 | PAPER RECEIVED | — | |
| Nov 10, 2006 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 24, 2006 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 24, 2006 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 23, 2006 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 22, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 13, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 13, 2006 | NWAP | NEW APPLICATION ENTERED | — |
| Oct 12, 2006 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |